Arcutis Begins Enrolling Phase 3 Study Evaluating ZORYVE® (roflumilast) Cream 0.3% in Moderate to Severe Atopic DermatitisGlobeNewsWire • 45m
Arcutis Biotherapeutics, Inc. (ARQT) Misses Q3 Earnings EstimatesZacks Investment Research • Wednesday
Arcutis Announces Third Quarter 2026 Financial Results and Provides Business UpdateGlobeNewsWire • Wednesday
Arcutis Biotherapeutics, Inc. (ARQT) Reports Next Week: Wall Street Expects Earnings GrowthZacks Investment Research • 10/28/26
Arcutis Management to Present at the Guggenheim 3rd Annual Healthcare Innovation ConferenceGlobeNewsWire • 10/27/26
Arcutis to Report Third Quarter 2026 Financial Results and Host Conference Call on November 4, 2026GlobeNewsWire • 10/21/26
Arcutis Presents ZORYVE® (roflumilast) Data and Real-World Topical Corticosteroid Research at EADV and Fall ClinicalGlobeNewsWire • 10/09/26
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewsWire • 10/02/26
Arcutis Biotherapeutics (ARQT) Moves 11.2% Higher: Will This Strength Last?Zacks Investment Research • 09/17/26
Arcutis Biotherapeutics, Inc. (ARQT) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptSeeking Alpha • 09/16/26
Arcutis Management to Present at the Morgan Stanley 24th Annual Global Healthcare ConferenceGlobeNewsWire • 09/02/26
Zacks Industry Outlook Halozyme, Repligen, Iovance, Arcutis and PrecigenZacks Investment Research • 08/27/26
Arcutis Biotherapeutics, Inc. (ARQT) Q2 Earnings and Revenues Surpass EstimatesZacks Investment Research • 08/05/26
Arcutis Announces Second Quarter 2026 Financial Results and Provides Business UpdateGlobeNewsWire • 08/05/26